News | Cardiac Imaging | September 23, 2021

Doctors say they should be making medical decisions with patients, not insurance carriers and outline principles for noninvasive testing

Doctors say they should be making medical decisions with patients, not insurance carriers and outline principles for noninvasive testing

September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by insurers’ test substitution policies, according to a statement published online in the Journal of the American College of Cardiology.[1] The statement summarizes the proceedings of a recent summit convened by the American Society of Nuclear Cardiology (ASNC), where six leading cardiovascular imaging organizations discussed challenges associated with test substitution.

The principles outlined in the statement were endorsed by the leadership of the American College of Cardiology Imaging Council, American Society of Echocardiography (ASE), ASNC, Society of Cardiovascular Computed Tomography (SCCT)Society for Cardiovascular Magnetic Resonance (SCMR), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Test substitution policies are defined as policies enacted by private insurers or their radiology benefits managers that require the substitution of one diagnostic test for another. These have become a troublesome trend in recent years, according to new statement.
 
The paper focuses on the potential impacts of test substitution on coronary artery disease assessment. The authors note that the few randomized trials comparing the various imaging modalities have generally described benefits and limitations with each modality and that guidelines and appropriate use criteria “include individualized risk assessment as a necessary prerequisite to deciding whether or not a test is needed, as well as test selection.”

“Cardiovascular test selection is highly nuanced and needs to reflect numerous variables, including individual patient factors, local expertise and access, and technology-related details,” said Sharmila Dorbala, M.D., MPH, MASNC, senior author of the statement and ASNC immediate past president. “Test substitution policies can lead to patients receiving the wrong test, unnecessary testing, and care delays. Insurers’ push to use a single first-line test in all patients with chest pain is not supported by evidence and may undermine a patient’s confidence in, and adherence to, their treatment plan.”

The authors call for more research on the impact of test substitution policies on cardiovascular outcomes, including the potential for subsequent additional testing and increased cost. They outline five consensus principles important for a “patient centric and personalized approach to chest pain imaging,” noting that “the key issue is the overall impact on health, taking into account patient preferences and the long-term cost-effectiveness of the strategy.”

The principles are as follows:
   • Optimal patient care should be the priority for physicians and insurance providers.
Given equivalent diagnostic accuracy and appropriate use criteria, there is no clear justification for routinely and indiscriminately recommending one diagnostic strategy over another.
   • Test substitution driven by short-term costs savings should not be endorsed.
   • In alignment with the principles of patient-centered medicine, a personalized approach to testing based on clinical information is better than one test for all patients.
   • Physicians are willing to accept guideline-directed management, relieving insurance providers of liability and reducing administrative burdens and cost.

“It is significant that representatives from all of the major cardiovascular imaging societies came together on this statement pointing out the problems with test substitution by insurance companies,” explained Randall C. Thompson, M.D., FASNC, the statement’s first author and ASNC’s current president. “While individual cardiologists may disagree on the optimal testing approach for an individual patient, there is strong consensus that these decisions are nuanced and should be made by expert physicians in the context of appropriate use and in collaboration with the patient – not by insurers’ algorithms. This statement points to the unmeasured harm that may be caused by overly assertive managed care and test substitution and calls for more research in this area.”

“A Policy Statement on Cardiovascular Test Substitution and Authorization: Principles of Patient-Centered Noninvasive Testing” (J Am Coll Cardiol 2021 Sep,78[13]:1385-9) echoes key points from ASNC’s 2011 position statement on the role of radiology benefits managers and private insurers in the physician-patient relationships. These documents underscore the ASNC’s long commitment to #PatientFirst clinical decision-making and test selection. Drs. Dorbala and Thompson are available for interviews.

Find more cardiac business stories

Reference:

1. Randall C. Thompson, Timothy M. Bateman, Ron Blankstein, et al. A Policy Statement on Cardiovascular Test Substitution and Authorization: Principles of Patient-Centered Noninvasive Testing. J Am Coll Cardiol. 2021 Sep, 78 (13) 1385–1389.
 


Related Content

News | Digital Radiography (DR)

February 8, 2023 — Carestream Health is partnering with Robarts Research Institute to increase and demonstrate the ...

Time February 08, 2023
arrow
News | Coronavirus (COVID-19)

February 8, 2023 — New data published in the Journal of Clinical Oncology further quantify the vast lingering impact of ...

Time February 08, 2023
arrow
Videos | Information Technology

A discussion on macro trends and the future of medical imaging with Jef Williams, managing partner, Paragon Consulting ...

Time February 07, 2023
arrow
News | Radiology Business

February 2, 2023 — Five additional imaging centers across Allegheny Health Network (AHN) have been recognized by the ...

Time February 02, 2023
arrow
News | MRI Breast

February 1, 2023 — Compared to other common supplemental screening methods, breast MRI was superior at detecting breast ...

Time February 01, 2023
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is a recap of what ITN viewers found most interesting during the month of January: 1. A Look at the Changes in 2023 ...

Time February 01, 2023
arrow
News | Ultrasound Imaging

January 31, 2023 — Esaote, a leading Italian company in the biomedical sector – in ultrasound, dedicated MRI and medical ...

Time January 31, 2023
arrow
News | Computed Tomography (CT)

January 30, 2023 — Photon-counting detector CT reduces the amount of contrast needed for CT angiography (CTA) while ...

Time January 30, 2023
arrow
News | Digital Pathology

January 27, 2023 — Fujifilm has completed its asset purchase of Inspirata, Inc.’s digital pathology business effective ...

Time January 27, 2023
arrow
News | Artificial Intelligence

January 27, 2023 — AiMed is excited to announce its collaboration with the College of Healthcare Information Management ...

Time January 27, 2023
arrow
Subscribe Now